Le Lézard
Classified in: Health
Subjects: TDS, MAT

New research from Shady Grove Fertility (SGF) can help provide an optimal age for egg donors and those pursuing elective egg freezing


Presented at the 78th ASRM Scientific Congress & Expo, SGF's research team offers reassurance for intended parents growing their family with the use of an egg donor and can offer guidance to patients pursuing elective egg freezing.

ROCKVILLE, Md., Oct. 26, 2022 /PRNewswire-PRWeb/ -- New research from Shady Grove Fertility (SGF) conducted with Donor Egg Bank USA offers reassurance for intended parents growing their family with the use of an egg donor and can offer guidance to patients pursuing elective egg freezing.

"Egg donation helps fulfill the dreams of parenthood for individuals and couples faced with infertility," shares Phillip A. Romanski, M.D., M.Sc., SGF physician. "At SGF, we pride ourselves in providing evidence-based fertility care; therefore, our research team conducted a study to help guide intended parents who are growing their family through egg donation."

The findings of SGF and Donor Egg Bank USA's study reassure patients using eggs from donors ages 21 through 32 yielded a similar ongoing pregnancy rate.

"We decided to conduct this study because some data have suggested an increase in chromosomal errors among the youngest infertility patients," adds Dr. Romanski. "Thankfully, we didn't find cause for significant concern among recipients of eggs from younger donors."

The study found that the pregnancy outcomes for each year of donor ages between 21 and 32 were comparable to donor eggs age 29.

The retrospective cohort study was conducted by SGF physicians Phillip A. Romanski, M.D., M.Sc., and Kate Devine, M.D., and Melissa Stratton B.A. and Wayne Caswell M.S. from Donor Egg Bank USA. The SGF research team looked at egg donor recipient cycles at Donor Egg Bank USA between 2013 and 2021. In total, the study looked at 3,678 donor egg cycles.

Dr. Romanski joins the SGF New York physician team this fall and provides patient care at SGF's Manhattan location. In spring 2023, Dr. Romanski will open SGF New York's SoHo location. He is board certified in Obstetrics and Gynecology and board eligible in Reproductive Endocrinology and Infertility. He specializes in third-party reproduction and egg freezing as well as diminished ovarian reserve, premature ovarian failure, and reproductive surgery. He serves as the Director of Research for SGF New York. At this year's ASRM national meeting, he will receive the "Star Reviewer" award from Fertility and Sterility for his exemplary service to the journal, and his research will also be awarded the "First Prize Video Research Award" by ASRM.

SGF is one of only a few private practice fertility centers in the country to employ a full-time dedicated research team, which operates under Director of Research, Kate Devine, M.D., a board certified reproductive endocrinologist who sees patients at SGF's Washington, D.C., K Street location. Dr. Devine also serves as the Executive Medical Director and Chief Research Officer at US Fertility, the largest network of physician-owned and physician-led fertility practices in the United States, of which SGF is a founding partner practice.

As a premier IVF and fertility center of excellence, SGF continues to make a sustained commitment to clinical research and educating physicians in training.

To learn more about ongoing research being conducted at SGF, visit http://www.shadygrovefertility.com/research.

About Shady Grove Fertility (SGF)
SGF is a leading fertility and IVF center of excellence with more than 100,000 babies born from 30+ years of continuous innovation and patient-centered fertility care. With 50 locations, including the newest location in Raleigh, North Carolina, as well as throughout CO, FL, GA, MD, NY, PA, TX, VA, D.C., and Santiago, Chile, SGF offers patients in-person and virtual physician consults, delivers individualized care, accepts most insurance plans, and makes treatment affordable through innovative financial options, including 100% refund guarantees. SGF is among the founding partner practices of US Fertility, the largest physician-led partnership of top-tier fertility practices in the U.S. Call 1-888-761-1967 to schedule a new patient appointment or visit ShadyGroveFertility.com for more information.

Media Contact

Jean Dzierzak, Shady Grove Fertility, 301-545-1375, [email protected]

 

SOURCE Shady Grove Fertility


These press releases may also interest you

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...

3 jui 2024
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...

3 jui 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...

3 jui 2024
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...



News published on and distributed by: